Equities research analysts expect Lipocine Inc (NASDAQ:LPCN) to announce earnings per share (EPS) of ($0.22) for the current quarter, Zacks reports. Zero analysts have made estimates for Lipocine’s earnings. Lipocine posted earnings per share of ($0.26) during the same quarter last year, which suggests a positive year over year growth rate of 15.4%. The business is scheduled to announce its next earnings results on Monday, May 14th.
On average, analysts expect that Lipocine will report full-year earnings of ($0.79) per share for the current fiscal year, with EPS estimates ranging from ($0.94) to ($0.63). For the next year, analysts anticipate that the business will post earnings of $0.47 per share, with EPS estimates ranging from ($0.73) to $1.67. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow Lipocine.
A number of research analysts have weighed in on the stock. Canaccord Genuity cut shares of Lipocine from a “buy” rating to a “hold” rating in a research report on Thursday, January 11th. Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $11.00 price objective on shares of Lipocine in a research report on Thursday, January 11th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Lipocine in a research report on Friday, December 8th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $13.50.
Shares of Lipocine (LPCN) opened at $1.48 on Tuesday. Lipocine has a 1 year low of $1.15 and a 1 year high of $5.33. The firm has a market cap of $33.49, a price-to-earnings ratio of -1.56 and a beta of 0.35.
Lipocine Company Profile
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.